Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BriaCell Therapeutics Corp (BCTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: BCTXW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -82.22% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.08M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.72 | 52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 |
52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.54% | Return on Equity (TTM) -688.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5776754 |
Shares Outstanding - | Shares Floating 5776754 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
BriaCell Therapeutics Corp
Company Overview
History and Background
BriaCell Therapeutics Corp is a biotechnology company focused on developing targeted immunotherapies for cancer. Founded in 2006, it has focused on developing its BriaVax immunotherapy platform.
Core Business Areas
- Immunotherapy Development: Focuses on developing and commercializing immunotherapies for advanced cancers, particularly breast cancer.
- BriaVax Platform: Develops and enhances the BriaVax targeted immunotherapy platform, researching its effectiveness against different cancers.
Leadership and Structure
The company is led by a management team with expertise in oncology and drug development. It has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- BriaVax: BriaVax is BriaCell's lead product candidate, an immunotherapy designed to activate a patient's immune system to fight cancer. Market share data is currently not available, and revenue from this product has not been achieved as it is still in clinical trials. Competitors developing immunotherapies for breast cancer include Merck (Keytruda) and Roche (Tecentriq).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing substantial growth, driven by advances in cancer research and personalized medicine. Demand is high for effective treatments with fewer side effects compared to traditional chemotherapy.
Positioning
BriaCell is positioned as an innovative immunotherapy company focusing on targeted treatments for advanced cancers. Its competitive advantage lies in its BriaVax platform and personalized approach.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach billions of dollars. BriaCell, while still in development stages, aims to capture a segment of this market through its BriaVax technology.
Upturn SWOT Analysis
Strengths
- Innovative immunotherapy platform
- Targeted approach to cancer treatment
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- No currently approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of BriaVax platform to other cancers
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- RO
- BMY
Competitive Landscape
BriaCell faces intense competition from larger pharmaceutical companies with established immunotherapy products. BriaCellu2019s advantage lies in its targeted approach and potential for personalized medicine, but it must overcome resource limitations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of the BriaVax platform through preclinical and clinical trials.
Future Projections: Future growth is highly dependent on the success of ongoing and planned clinical trials. Analyst projections vary but generally anticipate significant growth if BriaVax is approved.
Recent Initiatives: Recent initiatives include ongoing clinical trials for BriaVax in advanced breast cancer and efforts to expand the platform to other cancers.
Summary
BriaCell Therapeutics is a development-stage company focused on immunotherapies for cancer, particularly breast cancer. It needs to successfully navigate clinical trials and secure partnerships to thrive in a competitive market, as its current revenue is minimal, and its success depends largely on the BriaVax platform's performance. Potential successes in clinical trials may lead to a surge in value, which will require strategic management to ensure its longevity. However, clinical trial failures could seriously impair future results, as well as the value of the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. BriaCell Therapeutics is a speculative investment, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.